Given the demonstrated therapeutic benefit of IL-11 signaling inhibition in this model [15], we also sought to determine if the serum protein signatures that correlated with tumor progression were altered following therapeutic manipulation of tumor burden. The gene discussed is IL11; the disease is neoplasm.